Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network

Clinical Immunology

Volumn 133, Issue 1, 2009, Pages 108-116

  Keren, Zohar ^a   Braun Moscovici, Yolanda ^b   Markovits, Doron ^b   Rozin, Alexander ^b   Nahir, Menahem ^a,b   Balbir Gurman, Alexandra ^b   Melamed, Doron ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b B Shine Department of Rheumatology   (Israel)

Author keywords

Autoantibodies; B cell; IL 8; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIRHEUMATIC AGENT; AUTOANTIBODY; INFLIXIMAB; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; PROTHIAZINE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HUMAN; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SERUM; SYNOVIAL FLUID;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-8; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; SYNOVIAL FLUID;

EID: 69949145124     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.07.001     Document Type: Article

References (33)

1. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., and Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
2. Smolen J.S., Keystone E.C., Emery P., Breedveld F.C., Betteridge N., Burmester G.R., Dougados M., Ferraccioli G., Jaeger U., Klareskog L., Kvien T.K., Martin-Mola E., and Pavelka K. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66 (2007) 143-150
3. Edwards J.C., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6 (2006) 394-403
4. Goldblatt F., and Isenberg D.A. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb. Exp. Pharmacol. (2008) 163-181
5. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., and Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
6. Hu C.Y., Rodriguez-Pinto D., Du W., Ahuja A., Henegariu O., Wong F.S., Shlomchik M.J., and Wen L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117 (2007) 3857-3867
7. Mok C.C., Ho L.Y., and To C.H. Rituximab for refractory polymyositis: an open-label prospective study. J. Rheumatol. 34 (2007) 1864-1868
8. McFarland H.F. The B cell - old player, new position on the team. N. Engl. J. Med. 358 (2008) 664-665
9. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14 (1996) 397-440
10. Koch A.E., Kunkel S.L., and Strieter R.M. Cytokines in rheumatoid arthritis. J. Investig. Med. 43 (1995) 28-38
11. Wildbaum G., Nahir M.A., and Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 19 (2003) 679-688
12. Peichl P., Ceska M., Broell H., Effenberger F., and Lindley I.J. Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis. Ann. Rheum. Dis. 51 (1992) 19-22
13. Suzuki H., Ayabe T., Kamimura J., and Kashiwagi H. Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin. Exp. Immunol. 85 (1991) 407-412
14. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 19 (2001) 163-196
15. Lipsky P.E., van der Heijde D.M.F.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., Harriman G.R., and Maini R.N. The anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group, infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1594-1602
16. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., and Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340 (1999) 253-259
17. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., Keystone E.C., Loveless J.E., Burmester G.R., Cravets M.W., Hessey E.W., Shaw T., and Totoritis M.C. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54 (2006) 2793-2806
18. Youinou P. B cell conducts the lymphocyte orchestra. J. Autoimmun. 28 (2007) 143-151
19. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., Johnson L.L., Swain S.L., and Lund F.E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1 (2000) 475-482
20. Harada A., Sekido N., Akahoshi T., Wada T., Mukaida N., and Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J. Leukoc. Biol. 56 (1994) 559-564
21. Opdenakker G., Dillen C., Fiten P., Martens E., Van Aelst I., Van den Steen P.E., Nelissen I., Starckx S., Descamps F.J., Hu J., Piccard H., Van Damme J., Wormald M.R., Rudd P.M., and Dwek R.A. Remnant epitopes, autoimmunity and glycosylation. Biochim. Biophys. Acta 1760 (2006) 610-615
22. van Gestel A.M., Anderson J.J., van Riel P.L., Boers M., Haagsma C.J., Rich B., Wells G., Lange M.L., and Felson D.T. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J. Rheumatol. 26 (1999) 705-711
23. Peichl P., Pursch E., Broll H., and Lindley I.J. Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol. Int. 18 (1999) 141-145
24. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., and Willcox N. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132 (2003) 128-136
25. Kurdowska A., Miller E.J., Noble J.M., Baughman R.P., Matthay M.A., Brelsford W.G., and Cohen A.B. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome. J. Immunol. 157 (1996) 2699-2706
26. Kaser A., Mairinger T., Vogel W., and Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 113 (2001) 930-933
27. Higashida J., Wun T., Schmidt S., Naguwa S.M., and Tuscano J.M. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J. Rheumatol. 32 (2005) 2109-2115
28. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40 (2001) 205-211
29. Goldblatt F., and Isenberg D.A. New therapies for rheumatoid arthritis. Clin. Exp. Immunol. 140 (2005) 195-204
30. van der Meide P.H., and Schellekens H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy 10 (1997) 39-48
31. Okroj M., Heinegard D., Holmdahl R., and Blom A.M. Rheumatoid arthritis and the complement system. Ann. Med. 39 (2007) 517-530
32. Manz R.A., Hauser A.E., Hiepe F., and Radbruch A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23 (2005) 367-386
33. Cambridge G., Stohl W., Leandro M.J., Migone T.S., Hilbert D.M., and Edwards J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54 (2006) 723-732